The many faces of SRPK1.
The many faces of SRPK1.
复制标题
DOI：
10.1002/path.4846
复制
发表时间：
2017-03
期刊：
影响因子：
--
通讯作者：
Oltean S
中科院分区：
文献类型：
--
作者：
Bullock N;Oltean S
丝氨酸-精氨酸蛋白激酶1（SRPK 1）磷酸化参与调节多种mRNA加工途径的蛋白质，包括选择性剪接。SRPK 1最近被报道在多种癌症中过表达，包括前列腺癌、乳腺癌、肺癌和神经胶质瘤。一些研究表明，抑制SRPK 1具有抗肿瘤作用，因此SRPK 1已成为靶向治疗的新候选药物。有趣的是，就分子机制而言，SRPK 1似乎不均匀地起作用，并且已经报道影响不同癌症中的几个过程，例如前列腺癌和结肠癌中的血管生成，乳腺癌和结肠癌中的细胞凋亡，以及乳腺癌中的迁移。最近的一份报告增加了这一难题，表明SRPK 1在非小细胞肺癌中过表达的主要作用是刺激干细胞样表型。这种多效性可能与SRPK 1在各种癌症中优先激活不同下游信号通路有关。© 2016作者。病理学杂志由John Wiley & Sons Ltd代表大不列颠和爱尔兰病理学会出版。链接文章：Gong et al. J Pathol 2016; 240：184 - 196。
Serine–arginine protein kinase 1 (SRPK1) phosphorylates proteins involved in the regulation of several mRNA‐processing pathways, including alternative splicing. SRPK1 has been recently reported to be overexpressed in multiple cancers, including prostate cancer, breast cancer, lung cancer, and glioma. Several studies have shown that inhibition of SRPK1 has anti‐tumoural effects, and SRPK1 has therefore become a new candidate for targeted therapies. Interestingly, in terms of molecular mechanism, SRPK1 seems to act heterogeneously, and has been reported to affect several processes in different cancers, e.g. angiogenesis in prostate and colon cancer, apoptosis in breast and colon cancer, and migration in breast cancer. A recent report adds to this puzzle, showing that the main effect of SRPK1 overexpression in non‐small‐cell lung carcinoma is to stimulate a stem cell‐like phenotype. This pleiotropy might be related to preferential activation of different downstream signalling pathways by SRPK1 in various cancers. © 2016 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain and Ireland. Linked Article: Gong et al. J Pathol 2016; 240: 184‐196.